Patents Examined by T. M. Cunningham
  • Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
    Patent number: 5229289
    Abstract: A method of producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens comprising: (1) immunizing a host with a core structure of a mucin-type glycoprotein: (2) fusing splenocytes from said immunized host with myeloma cells to form hybridoma cells; (3) culturing said hybridoma cells on selective medium; (4) selecting hybridoma cells surviving step (3) that secrete antibody that binds to said core structure of a mucin-type glycoprotein; (5) cloning said selected hybridoma cells from step (4); (6) culturing said cloned hybridoma cells; and (7) recovering said antibody. Hybridomas and monoclonal antibodies produced by the above-described method. Methods of passive and active immunization employing the monoclonal antibodies and mucin-type glycoproteins or synthetic oligosaccharide-carrier conjugates.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: July 20, 1993
    Assignee: The Biomembrane Institute
    Inventors: Thomas J. Kjeldsen, Henrik Clausen, Anil Singhal, Tatsushi Toyokuni, Helio Takahashi, Sen-itiroh Hakomori
  • Established cell line, KML.sub.1-7, which produces B-cell differentiation factor (BCDF)
    Patent number: 5132222
    Abstract: A novel established cell line, KML.sub.1-7, obtained by collecting lymphoid cells from an animal with autoimmune disease, culturing them in a culture medium containing the supernatant of a culture in which lymphoid cells of animal origin have been grown in the presence of a mitogen, and continuing the culture for a period of 8 months until the cells are able to grow in the absence of the aforesaid supernatant. This established cell line has the following properties.(1) It produces a factor, B-Cell Differentiation Factor (BCDF), participating in the differentiation of antibody-producing cells.(2) It does not produce B cell growth factor.(3) It consists of immortalized null cells.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: July 21, 1992
    Assignee: Mitsui Toatsu Chemicals Incorporated
    Inventors: Yoshiyuki Kanai, Akira Awaya
  • Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
    Patent number: 5124153
    Abstract: Non-virulent bacteria are disclosed into which have been cloned heterologous nucleotide sequences encoded for the expression of Streptococcal M protein antigens, which are effective to elicit opsonic antibodies against Streptococcal infections. These bacteria are useful for vaccination against Streptococcus pyogenes bacteria.
    Type: Grant
    Filed: August 9, 1989
    Date of Patent: June 23, 1992
    Assignee: University of Tennessee Research Corp.
    Inventors: Edwin H. Beachey, Thomas P. Poirier, Michael A. Kehoe
  • Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
    Patent number: 5011912
    Abstract: A particular calcium-dependent monoclonal antibody, 4E11, is produced from a murine hybridoma cell line and is useful for purifying a recombinant fusion protein having an N-terminal identification peptide DYKDDDDK to which the monoclonal antibody binds.
    Type: Grant
    Filed: April 10, 1989
    Date of Patent: April 30, 1991
    Assignee: Immunex Corporation
    Inventors: Thomas P. Hopp, Kathryn S. Prickett